EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte Studie

A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide

Ann Marie Navar, Elina Mikhailova, Alberico L Catapano, Puja Banka, Dirk J Blom, Alberto Cadena, Susan Kourpanidis, Norman E Lepor, Kazuhisa Tsukamoto, Geraldine Mendizabal, Julio Nunez, Wenjuan Zhang und 4 weitere

New England Journal of Medicine · 05.02.2026 · 394 (6) · 529-539

DOI: 10.1056/nejmoa2511002 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 05.02.2026. Verfasst von Ann Marie Navar und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas. Hauptthemen laut MEDLINE: Atherosclerosis, Cardiovascular Diseases, Cholesterol, LDL, Hypercholesterolemia. Die Arbeit wurde bisher 66-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Merck Sharp and Dohme LLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AtherosclerosisCardiovascular DiseasesCholesterol, LDLHypercholesterolemiaPCSK9 InhibitorsAgedFemaleHumansMaleMiddle AgedAdministration, OralApolipoproteins BAza CompoundsDouble-Blind MethodLipoprotein(a)PyrrolidinesTreatment OutcomeTriazoles

Substanzen

Apolipoproteins BAza CompoundsCholesterol, LDLLipoprotein(a)LPA protein, humanMK-0616PCSK9 InhibitorsPyrrolidinesTriazoles

Autor:innen und Institutionen

  • Department of Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas.
  • MSD UK, London.
  • University of Milan, Milan.
  • IRCCS Multimedica, Milan.
  • MSD, Rahway, NJ.
  • University of Cape Town, Cape Town, South Africa.

Förderung

  • Merck Sharp and Dohme LLC

Zitieren

APA

Navar, A. M., Mikhailova, E., Catapano, A. L., Banka, P., Blom, D. J., Cadena, A., Kourpanidis, S., Lepor, N. E., Tsukamoto, K., Mendizabal, G., Nunez, J., Zhang, W., Zhu, P., Zhuo, M., Ballantyne, C. M., & CORALreef Lipids Investigators (2026). A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide. New England Journal of Medicine, 394(6), 529-539. https://doi.org/10.1056/nejmoa2511002

Vancouver

Navar AM, Mikhailova E, Catapano AL, Banka P, Blom DJ, Cadena A, et al. A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide. New England Journal of Medicine. 2026;394(6):529-539. doi:10.1056/nejmoa2511002

BibTeX
@article{Navar2026,
  author = {Navar, Ann Marie and Mikhailova, Elina and Catapano, Alberico L and Banka, Puja and Blom, Dirk J and Cadena, Alberto and Kourpanidis, Susan and Lepor, Norman E and Tsukamoto, Kazuhisa and Mendizabal, Geraldine and Nunez, Julio and Zhang, Wenjuan and Zhu, Pengfei and Zhuo, Min and Ballantyne, Christie M and CORALreef Lipids Investigators, CORALreef Lipids Investigators},
  title = {A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {394},
  number = {6},
  pages = {529--539},
  doi = {10.1056/nejmoa2511002}
}
Kostenlos starten →